Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3061% above fair value

$253.62+3.97 (+1.59%)

Close on Oct 30, 2026Market cap $37.47BP/E 44.9Yield –

Earnings

Biogen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Jan 13, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

$2.80B

Non-GAAP diluted EPS, Q3 FY2026

$2.62

Latest guidance

Issued

Oct 28, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Biogen's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Jan 13, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 28, 2026before the open	$2.80B	–	-$0.14	$2.62	Release
Q2 FY2026ended Jun 30, 2026	Jul 1, 2026after the close	–	–	–	–	Filing
Q1 FY2026ended Mar 31, 2026	Apr 6, 2026before the open	–	–	–	–	Filing
Q4 FY2025ended Dec 31, 2025	Jan 14, 2026after the close	–	–	–	–	Filing
Q3 FY2025ended Sep 30, 2025	Oct 14, 2025after the close	–	–	–	–	Filing
Q2 FY2025ended Jun 30, 2025	Jul 7, 2025after the close	–	–	–	–	Filing
Q1 FY2025ended Mar 31, 2025	May 1, 2025before the open	$2.40B	+4.3%	$1.64	$3.02	Release
Q4 FY2024ended Dec 31, 2024	Feb 12, 2025before the open	$2.50B	+4.2%	$1.83	$3.44	Release
Q3 FY2024ended Sep 30, 2024	Oct 30, 2024before the open	$2.50B	-1.2%	$2.66	$4.08	Release
Q2 FY2024ended Jun 30, 2024	Aug 1, 2024before the open	$2.50B	+1.8%	$4.00	$5.28	Release
Q1 FY2024ended Mar 31, 2024	Apr 24, 2024before the open	$2.30B	-6.6%	$2.70	$3.67	Release
Q4 FY2023ended Dec 31, 2023	Feb 13, 2024before the open	$2.40B	-5.7%	$1.71	$2.95	Release
Q3 FY2023ended Sep 30, 2023	Nov 8, 2023before the open	$2.53B	+0.9%	-$0.47	$4.36	Release
Q2 FY2023ended Jun 30, 2023	Jul 25, 2023before the open	$2.46B	-5.1%	$4.07	$4.02	Release
Q1 FY2023ended Mar 31, 2023	Apr 25, 2023before the open	$2.46B	-2.7%	$2.67	$3.40	Release
Q4 FY2022ended Dec 31, 2022	Feb 15, 2023before the open	$2.54B	-6.9%	$3.79	$4.05	Release
Q3 FY2022ended Sep 30, 2022	Oct 25, 2022before the open	$2.51B	-9.8%	$7.84	$4.77	Release
Q2 FY2022ended Jun 30, 2022	Jul 20, 2022before the open	$2.59B	–	$7.24	$5.25	Release
Q1 FY2022ended Mar 31, 2022	May 3, 2022before the open	$2.53B	–	$2.06	$3.62	Release
Q4 FY2021ended Dec 31, 2021	Feb 3, 2022before the open	$2.73B	–	$2.50	$3.39	Release
Q3 FY2021ended Sep 30, 2021	Oct 20, 2021before the open	$2.78B	–	$2.22	$4.77	Release
Q2 FY2021ended Jun 30, 2021	Jul 22, 2021before the open	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	Apr 22, 2021before the open	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 3, 2021before the open	–	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 21, 2020before the open	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Biogen's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Non-GAAP diluted EPSnon-GAAP	FY2026	$12.20 – $13.00	–	New	Oct 28, 2026
combined Non-GAAP R&D expense and Non-GAAP SG&A expensenon-GAAP	FY2026	$4.95B	–	New	Oct 28, 2026

Guidance history

Every forecast Biogen put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 28, 2026	Non-GAAP diluted EPS	FY2026	$12.20 – $13.00	New
Oct 28, 2026	combined Non-GAAP R&D expense and Non-GAAP SG&A expense	FY2026	$4.95B	New
May 1, 2025	Non-GAAP diluted EPS	FY2025	$14.50 – $15.50	Lowered
May 1, 2025	combined Non-GAAP R&D expense and Non-GAAP SG&A expense	FY2025	$3.90B	Reaffirmed
Feb 12, 2025	Non-GAAP diluted EPS	FY2025	$15.25 – $16.25	New
Feb 12, 2025	combined Non-GAAP R&D expense and Non-GAAP SG&A expense	FY2025	$3.90B	New
Oct 30, 2024	Non-GAAP diluted EPS	FY2024	$16.10 – $16.60	Raised
Aug 1, 2024	Non-GAAP EPS	FY2024	$15.75 – $16.25	Raised
Apr 24, 2024	Non-GAAP EPS	FY2024	$15.00 – $16.00	Reaffirmed
Feb 13, 2024	Non-GAAP EPS	FY2024	$15.00 – $16.00	New
Nov 8, 2023	Non-GAAP diluted EPS	FY2023	$14.50 – $15.00	Lowered
Jul 25, 2023	Non-GAAP diluted EPS	FY2023	$15.00 – $16.00	Reaffirmed
Apr 25, 2023	Non-GAAP diluted EPS	FY2023	$15.00 – $16.00	Reaffirmed
Feb 15, 2023	Non-GAAP EPS	FY2023	$15.00 – $16.00	New
Oct 25, 2022	Non-GAAP diluted EPS	FY2022	$16.50 – $17.15	Raised
Oct 25, 2022	Non-GAAP tax rate	FY2022	15.5% – 16.5%	Reaffirmed
Oct 25, 2022	Non-GAAP R&D expense	FY2022	$2.20B – $2.30B	Lowered
Oct 25, 2022	Non-GAAP SG&A expense	FY2022	$2.30B – $2.40B	Raised
Oct 25, 2022	Total revenue	FY2022	$10.00B – $10.15B	Raised
Jul 20, 2022	Non-GAAP diluted EPS	FY2022	$15.25 – $16.75	Raised
Jul 20, 2022	Non-GAAP tax rate	FY2022	15.5% – 16.5%	Reaffirmed
Jul 20, 2022	Non-GAAP R&D expense	FY2022	$2.20B – $2.30B	Lowered
Jul 20, 2022	Non-GAAP SG&A expense	FY2022	$2.30B – $2.40B	Raised
Jul 20, 2022	Total revenue	FY2022	$9.90B – $10.10B	Raised
May 3, 2022	Non-GAAP diluted EPS	FY2022	$14.25 – $16.00	Reaffirmed
May 3, 2022	Non-GAAP tax rate	FY2022	15.5% – 16.5%	Reaffirmed
May 3, 2022	Non-GAAP R&D expense	FY2022	$2.20B – $2.30B	Lowered
May 3, 2022	Non-GAAP SG&A expense	FY2022	$2.30B – $2.40B	Raised
May 3, 2022	Total revenue	FY2022	$9.70B – $10.00B	New
Feb 3, 2022	Non-GAAP diluted EPS	FY2022	$14.25 – $16.00	New
Feb 3, 2022	Non-GAAP tax rate	FY2022	15.5% – 16.5%	New
Feb 3, 2022	Non-GAAP R&D expense	FY2022	$2.20B – $2.30B	New
Feb 3, 2022	Non-GAAP SG&A expense	FY2022	$2.50B – $2.60B	Raised
Feb 3, 2022	revenue	FY2022	$9.70B – $10.00B	New
Oct 20, 2021	Capital expenditures	FY2021	$250.00M – $300.00M	New
Oct 20, 2021	Non-GAAP diluted EPS	FY2021	$18.85 – $19.35	New
Oct 20, 2021	Non-GAAP R&D expense	FY2021	$2.45B – $2.55B	New
Oct 20, 2021	Non-GAAP SG&A expense	FY2021	$2.60B – $2.70B	Raised
Oct 20, 2021	Total revenue	FY2021	$10.80B – $10.90B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.